Imaging of myocardial infarction using ultrasmall superparamagnetic iron oxide nanoparticles: a human study using a multi-parametric cardiovascular magnetic resonance imaging approach.

AIMS The purpose of this clinical trial was to investigate whether cardiovascular magnetic resonance imaging (CMR) using ferumoxytol (Feraheme™, FH), an ultrasmall superparamagnetic iron oxide nanoparticle (USPIO), allows more detailed characterization of infarct pathology compared with conventional gadolinium-based necrosis/fibrosis imaging in patients with acute myocardial infarction. METHODS AND RESULTS Fourteen patients who had experienced an acute ST-elevation myocardial infarction were included in this study. Following coronary angiography, a first baseline study (pre-FH) was performed followed by subsequent CMR studies (post-FH) 48 h after intravenous ferumoxytol administration. The CMR studies comprised cine-CMR, T(2)-weighted short tau inversion recovery spin echo imaging, T(2)-mapping, and T(1)-weighted late gadolinium enhancement (LGE) imaging. The median extent of short-axis in-plane LGE was 30% [inter-quartile range (IQR) 26-40%]. The median in-plane extent of T(2)-weighted 'hypoenhancement' in the region of myocardial infarction, which was not present prior to ferumoxytol administration in any patient, was 19% (IQR 14-22%; P < 0.001 compared with the extent of LGE). The median in-plane extent of areas showing signal void in T(2)-mapping images post-FH in the region of myocardial infarction was 16% (IQR 12-18%; P < 0.001 compared with the extent of LGE; P = 0.34 compared with the extent of T(2)-weighted hypoenhancement). A substantial drop in absolute T(2)-values was observed not only in the infarct core and peri-infarct zone, but also in the remote 'healthy' myocardium, although there was only a minor change in the skeletal muscle. Substantial ferumoxytol uptake was detected only in cultured macrophages, but not in peripheral blood monocytes from study patients. CONCLUSION We could demonstrate in humans that USPIO-based contrast agents enable a more detailed characterization of myocardial infarct pathology mainly by detecting infiltrating macrophages. Considering the multi-functionality of USPIO-based particles and their superior safety profile compared with gadolinium-based compounds, these observations open up new vistas for the clinical application of USPIO.

[1]  Ahmed Tawakol,et al.  PET/MRI of inflammation in myocardial infarction. , 2012, Journal of the American College of Cardiology.

[2]  K. Scheffler,et al.  Principles and applications of balanced SSFP techniques , 2003, European Radiology.

[3]  G. Schuler,et al.  Prognostic value and determinants of a hypointense core in T2-weighted cardiac magnetic resonance in acute reperfused ST-elevation myocardial infarction , 2011, Circulation. Cardiovascular imaging.

[4]  M. Schieber,et al.  Comparative Evaluation of Left and Right Ventricular Endomyocardial Biopsy: Differences in Complication Rate and Diagnostic Performance , 2010, Circulation.

[5]  Vasilis Ntziachristos,et al.  Fluorescence Tomography and Magnetic Resonance Imaging of Myocardial Macrophage Infiltration in Infarcted Myocardium In Vivo , 2007, Circulation.

[6]  Tom MacGillivray,et al.  Ultrasmall Superparamagnetic Particles of Iron Oxide in Patients With Acute Myocardial Infarction: Early Clinical Experience , 2012, Circulation. Cardiovascular imaging.

[7]  F. Franconi,et al.  High Field Magnetic Resonance Imaging Evaluation of Superparamagnetic Iron Oxide Nanoparticles in a Permanent Rat Myocardial Infarction , 2003, Investigative radiology.

[8]  Einar Heiberg,et al.  Rapid Initial Reduction of Hyperenhanced Myocardium After Reperfused First Myocardial Infarction Suggests Recovery of the Peri-Infarction Zone: One-Year Follow-Up by MRI , 2009, Circulation. Cardiovascular imaging.

[9]  Olga Bondarenko,et al.  Standardizing the definition of hyperenhancement in the quantitative assessment of infarct size and myocardial viability using delayed contrast-enhanced CMR. , 2005, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

[10]  P. Libby,et al.  Impaired infarct healing in atherosclerotic mice with Ly-6C(hi) monocytosis. , 2010, Journal of the American College of Cardiology.

[11]  W. Stevenson,et al.  Characterization of the Peri-Infarct Zone by Contrast-Enhanced Cardiac Magnetic Resonance Imaging Is a Powerful Predictor of Post–Myocardial Infarction Mortality , 2006, Circulation.

[12]  M. Entman,et al.  Of mice and dogs: species-specific differences in the inflammatory response following myocardial infarction. , 2004, The American journal of pathology.

[13]  R. Jennings,et al.  The Changing Anatomic Reference Base of Evolving Myocardial Infarction: Underestimation of Myocardial Collateral Blood Flow and Overestimation of Experimental Anatomic Infarct Size Due to Tissue Edema, Hemorrhage and Acute Inflammation , 1979, Circulation.

[14]  Vivek Muthurangu,et al.  Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance. , 2011, JACC. Cardiovascular imaging.

[15]  Warren J Manning,et al.  Clinical indications for cardiovascular magnetic resonance (CMR): Consensus Panel report. , 2004, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

[16]  M. Pittet,et al.  Monocytes: protagonists of infarct inflammation and repair after myocardial infarction. , 2010, Circulation.

[17]  P. Libby,et al.  Rapid monocyte kinetics in acute myocardial infarction are sustained by extramedullary monocytopoiesis , 2012, The Journal of experimental medicine.

[18]  William D Rooney,et al.  Superparamagnetic Iron Oxide Nanoparticles: Diagnostic Magnetic Resonance Imaging and Potential Therapeutic Applications in Neurooncology and Central Nervous System Inflammatory Pathologies, a Review , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[19]  Matthias Gutberlet,et al.  Cardiac magnetic resonance imaging parameters as surrogate endpoints in clinical trials of acute myocardial infarction , 2011, Trials.

[20]  B. Gersh,et al.  Thrombolysis and Myocardial Salvage Results of Clinical Trials and the Animal Paradigm‐ Paradoxic or Predictable? , 1993, Circulation.

[21]  Ernst J. Rummeny,et al.  Capacity of human monocytes to phagocytose approved iron oxide MR contrast agents in vitro , 2004, European Radiology.

[22]  辻岡 洋人.  Impact of heterogeneity of human peripheral blood monocyte subsets on myocardial salvage in patients with primary acute myocardial infarction , 2011 .

[23]  B. Gersh.  Impact of Primary Coronary Angioplasty Delay on Myocardial Salvage, Infarct Size, and Microvascular Damage in Patients With ST-Segment Elevation Myocardial Infarction: Insight From Cardiovascular Magnetic Resonance , 2010 .

[24]  K. Klingel,et al.  Diagnostic synergy of non-invasive cardiovascular magnetic resonance and invasive endomyocardial biopsy in troponin-positive patients without coronary artery disease. , 2009, European heart journal.

[25]  S. Plein,et al.  Reperfusion haemorrhage as determined by cardiovascular MRI is a predictor of adverse left ventricular remodelling and markers of late arrhythmic risk , 2010, Heart.

[26]  Ali Yilmaz,et al.  Magnetic resonance imaging (MRI) of inflamed myocardium using iron oxide nanoparticles in patients with acute myocardial infarction - preliminary results. , 2013, International journal of cardiology.

[27]  V. Wright,et al.  Bright-Blood T2-Weighted MRI Has High Diagnostic Accuracy for Myocardial Hemorrhage in Myocardial Infarction: A Preclinical Validation Study in Swine , 2011, Circulation. Cardiovascular imaging.

[28]  Antony K. Chen,et al.  Superparamagnetic Iron Oxide Nanoparticle Probes for Molecular Imaging , 2006, Annals of Biomedical Engineering.